课题基金 / 基金详情

Improving patient important outcomes for hemodialysis patients using pharmacological and dialysis-based strategies

Improving patient important outcomes for hemodialysis patients using pharmacological and dialysis-based strategies
使用药理学和基于透析的策略改善血液透析患者的患者重要结果
批准号:
302212
负责人:
Walsh Michael W
金额:
$21.86万
依托单位:
依托单位国家:
加拿大
项目类别:
Salary Programs
财政年份:
2013
资助国家:
加拿大
项目状态:
已结题
起止时间:
2013-12-01 至 2018-12-01

项目摘要

项目成果

Walsh Michael W的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Over 2 million people worldwide receive kidney dialysis because of kidney failure. Although dialysis sustains life, patients who require dialysis often suffer from chronic pain, nausea, fatigue and other symptoms that substantially reduce their quality of
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Glucocorticoids or Avacopan in peopLe with high-risk renal Anti-Neutrophil cytoplasm antibody associated vasculitis Trial (GALANT) - Pilot
  • 批准号:
    489796
  • 项目类别:
    Operating Grants
  • 资助金额:
    $37.9万
  • 财政年份:
    2023
  • 负责人:
    Walsh Michael W
  • 依托单位:
Aldosterone blockade for Health Improvement Evaluation in End-stage kidney disease: Extension
  • 批准号:
    461992
  • 项目类别:
    Operating Grants
  • 资助金额:
    $88.05万
  • 财政年份:
    2022
  • 负责人:
    Walsh Michael W
  • 依托单位:
Protection of the heart with aldosterone antagonism in end-stage renal disease (PHASE 2) Trial
  • 批准号:
    333015
  • 项目类别:
    Operating Grants
  • 资助金额:
    $7.29万
  • 财政年份:
    2015
  • 负责人:
    Walsh Michael W
  • 依托单位:
Plasma exchange and glucocorticoid dosing in the treatment of anti-neutrophil cytoplasm antibody associated vasculitis: extended follow-up of a randomized controlled trial
  • 批准号:
    322606
  • 项目类别:
    Operating Grants
  • 资助金额:
    $24.76万
  • 财政年份:
    2015
  • 负责人:
    Walsh Michael W
  • 依托单位:
海外基金